The news this week that the Omnipod insulin pump had finally received Medicare coverage brought cheers from diabetes advocates and physicians alike—at long last, the popular tubeless device might soon be available to beneficiaries after a baffling odyssey, years after it received FDA clearance in 2005.
The action came after CMS opted not to classify the pump, made by Insulet Corp, as durable medical equipment eligible (DME) for coverage under Medicare Part B, but instead as a medical supply associated with insulin injection. Thus, Omnipod will be made available under Medicare Part D, and it will be distributed through the pharmacy chain, which Insulet’s Dan Trodden, vice president for Market Access, said the company believes will lead to a superior consumer experience.
For years, CMS refused to pay for Omnipod because its insulin delivery mechanism was disposable, even though the bulk of the device lasted more than 3 years, which is the test a device must meet for reimbursement under the definition of DME.
In the end, said Trodden, it appears CMS’ decision was finally driven by the Medicare Modernization Act, which President George W. Bush signed in late 2003. “That language did actually indicate that a medical supply that is directly associated with injecting insulin into the body,” that is not otherwise covered by Part B, should be covered by the Part D drug plan. “It took a long time for CMS to process that,” Trodden said.
CMS’ change of heart comes on the heels of 2 events that observers say forced regulators to take notice. First, last July, the Government Accountability Office (GAO) issued a report that said CMS’ approach to paying for medical technology was stifling innovation. Without naming Omnipod it clearly referenced the agency’s head-scratching refusal to cover the pump.
Second, the recent retreat of several pump makers from the market, including Johnson & Johnson’s decision in October to take the Animas pump off the market, caught CMS’ attention, Trodden said.
“When you have an organization like Johnson & Johnson leave the market, that’s really a significant event,” he said. The GAO’s prediction that CMS’ refusal to think broadly could stifle innovation—and leave patients with fewer choices—was coming to pass.
Insulet is still the smaller player in a pump market dominated by Medtronic, but CMS’ willingness to think differently leaves Trodden optimistic that the agency is starting to “catch up with innovation.”
Which is important, because a wave of smaller, less expensive, devices are about to hit the market—including another factory calibrated continuous glucose monitor (CGM) from Dexcom. In the past week, CMS granted reimbursement approval for Abbott’s factory calibrated CGM, the Freestyle Libre. (Abbott will also pursue distribution through the pharmacy chain).
For Trodden and Insulet, the work now is getting formulary access in Medicare plans; Trodden said Insulet will focus on securing the best possible formulary placement to keep cost-sharing low.
“Access to appropriate technology is paramount for people living with diabetes and is a key priority for our organization,” Shacey Petrovic, president and chief operating office, said in a statement. “With a low up-front cost and unique, disposable 3-day wear, the pharmacy channel is a natural fit for Omnipod and will provide Omnipod users an even better customer experience with broader and easier access to our unique platform through their pharmacy benefits.”
CMS’ decision “allows access for lower-income individuals and families on Medicaid for whom Omnipod is currently not an option,” the company said in the statement.
Research Points to Potential MCIDs in Diabetes Distress Scale–17
November 29th 2023Researchers identified a value of at least 0.25 to be a minimal clinically important difference (MCID) in diabetes distress, and MCID values of 0.38 and 0.39 for emotional and interpersonal distress subscales and physician and regimen distress subscales, respectively.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Oncology Onward: A Conversation With Dr Debra Patt of Texas Oncology
August 1st 2023Debra Patt, MD, PhD, MBA, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for episode 2 of our newest podcast, "Oncology Onward: Conversations With Innovators and Changemakers in Cancer Care."
Listen
What We’re Reading: UnitedHealth Lawsuit; Fentanyl Crackdown; Global Heat Deaths Increase
November 15th 2023A class action lawsuit was filed against UnitedHealth Group and a subsidiary for allegedly using an algorithm to deny rehabilitation coverage for seriously ill patients; US and China officials are finalizing an agreement to crack down on fentanyl; a study published Tuesday projected global heat deaths to increase by 370% if no action is taken against global warming.
Read More
Study Reveals Factors That Further Increase Colorectal Cancer Risk for Adults With T2D
November 14th 2023The strongest associations between diabetes and colorectal cancer risk were observed in participants with a recent diabetes diagnosis and those who had not undergone recent colonoscopy, underscoring the significance of cancer screening.
Read More